#AHA20 – RCT: Sotagliflozin improved cardiovascular outcomes in patients with Diabetes and CKD. Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk – SCORED – American College of Cardiology